Eucalyptus Health

Eucalyptus Health is an Australian digital-health company founded in 2019 and headquartered in Sydney. It provides online medical consultations, electronic prescriptions, health coaching, and medication fulfillment through partner pharmacies. Rather than operating as a single general-purpose consumer brand, the company has built a portfolio of specialized services aimed at particular health concerns and patient groups. The business began with Pilot, a men's-health telehealth service addressing conditions including erectile dysfunction, premature ejaculation, hair loss, and weight management. It later expanded into Juniper for women's weight management and menopause care, Software for online dermatology and prescription skincare, and Kin for contraception, fertility support, and pregnancy-related services. Compound, a men's preventive-health program, was introduced in 2024, paused later that year, and subsequently relaunched in the United Kingdom in 2025. Eucalyptus's model combines digital intake and clinical consultations with prescriptions supplied through pharmacy partners. Its expansion reflects the broader growth of consumer telehealth, particularly in areas where patients may face stigma, convenience barriers, or limited access to specialist care. The company has also expanded beyond Australia into the United Kingdom, Germany, Japan, and Canada. It became the first Australian telehealth company accredited by the Australian Council on Healthcare Standards under the EQuIP6 framework for the safety and quality of clinical services. The company attracted substantial venture funding during its expansion. Publicly reported rounds included an A$8 million Series A in 2020, a $30 million Series B in 2021, a $60 million Series C in 2022, and a further A$50 million round in 2023. The business was reported to have reached a valuation of approximately $560 million in 2023. It also acquired the digital assets of Jenny Craig Australia after that business entered voluntary administration in 2023. Eucalyptus has faced scrutiny over the clinical and marketing practices associated with online prescribing, particularly weight-management services involving GLP-1 medicines. Medical organizations and regulators questioned whether questionnaire-based prescribing provided sufficient clinical assessment, while concerns were also raised about direct-to-consumer promotion of prescription medicines, compounded semaglutide during shortages, influencer marketing, and the boundary between editorial coverage and advertising. The company responded in part by adding telephone-based general-practitioner consultations. Further debate followed the introduction of an artificial-intelligence chatbot and aggressive weight-loss marketing during a period of heightened public concern about eating disorders and the use of GLP-1 medicines. The company was acquired by Hims & Hers Health in a transaction announced in February 2026 and completed on June 2, 2026. The deal was reported as being worth up to US$1.15 billion, subject to closing, deferred, and earn-out payments. After completion, Eucalyptus became part of Hims & Hers Health's international consumer-health platform, while co-founder and chief executive Tim Doyle moved into an international operations leadership role at the acquiring company.

Eucalyptus Health was established in Australia in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko. Its first major service was Pilot, a telehealth brand focused on men's health. Pilot used online clinical workflows to connect patients with medical assessment, prescriptions, and pharmacy fulfillment for conditions such as erectile dysfunction, premature ejaculation, hair loss, and weight management. The company subsequently developed a multi-brand structure. Juniper extended the model into women's health, particularly weight management and menopause care. Software added online dermatology consultations and prescription skincare, while Kin focused on reproductive health, including contraception, fertility assistance, and pregnancy care. Compound, a men's preventive-health service, was launched in 2024, paused later that year, and relaunched in the United Kingdom in 2025. Eucalyptus expanded internationally into the United Kingdom, Germany, Japan, and Canada. Its operating model centers on digital patient acquisition and consultation, clinician-led treatment decisions, electronic prescriptions, and delivery through pharmacy partners. The company was recognized as the first telehealth company in Australia to receive accreditation from the Australian Council on Healthcare Standards against the EQuIP6 standards for clinical safety and quality. Funding supported the company's rapid growth. Reported financing included an A$8 million Series A in May 2020, a $30 million Series B in July 2021, and a $60 million Series C in January 2022. In 2022, the company reduced its workforce by approximately 20% after an unnamed investment firm withdrew from a proposed lending arrangement. In 2023, Eucalyptus raised an additional A$50 million and was reported to have a valuation of approximately $560 million. It also acquired the digital assets of Jenny Craig Australia after that company entered voluntary administration. Weight management became an especially important part of the portfolio through Juniper's use of GLP-1 receptor agonists and associated health coaching. This expansion brought substantial regulatory and professional scrutiny. The Royal Australian College of General Practitioners questioned whether remote questionnaires were sufficient for prescribing GLP-1 medicines, while the Therapeutic Goods Administration warned online providers about the direct advertising of prescription-only drugs. During shortages in 2023 and 2024, Eucalyptus's use of compounding pharmacies to provide compounded semaglutide attracted criticism from manufacturers and regulators. Australia subsequently prohibited pharmacy compounding of GLP-1 drugs from October 2024. Media and advocacy criticism also focused on marketing. Reports questioned whether influencer and social-media campaigns overstated treatment outcomes, and ABC's Media Watch examined whether television coverage promoting the company's services adequately distinguished editorial content from advertising. Eating-disorder organizations later expressed concern that rapid GLP-1 expansion and promotional campaigns, including a Juniper Black Friday sale, could encourage treatment among people who did not clinically require it. Eucalyptus responded to some clinical-process criticism by introducing telephone-based general-practitioner consultations in place of purely asynchronous online forms. In 2025, the TGA issued class-wide safety warnings for GLP-1 and dual GIP/GLP-1 medicines regarding aspiration risks during general anesthesia, and Eucalyptus's introduction of an AI chatbot prompted further debate about automation in weight-loss care. The company was acquired by Hims & Hers Health in a transaction announced in February 2026 and completed on June 2, 2026. The reported consideration was up to US$1.15 billion, comprising a payment at closing, deferred cash or stock, and earn-out payments tied to financial targets through 2029. Following completion, Eucalyptus became part of Hims & Hers Health's international consumer-health operations. Tim Doyle moved from Eucalyptus's chief executive role to senior vice president of international operations at Hims & Hers.

• 2026

  Acquisition by Hims & Hers closes

  [1]Eucalyptus Healthen.wikipedia.org

  Eucalyptus becomes part of Hims & Hers Health on June 2, 2026.

• 2024

  Compound launches

  [1]Eucalyptus Healthen.wikipedia.org

  The company introduces Compound, a men's preventive-health program.

• 2023

  Jenny Craig Australia digital assets acquired

  [1]Eucalyptus Healthen.wikipedia.org

  Eucalyptus acquires digital assets from Jenny Craig Australia after the business enters voluntary administration.

• 2022

  Series C financing and workforce reduction

  [1]Eucalyptus Healthen.wikipedia.org

  Eucalyptus raises a reported $60 million Series C and later cuts approximately 20% of its workforce.

• 2021

  Series B financing

  [1]Eucalyptus Healthen.wikipedia.org

  The company raises a reported $30 million Series B.

• 2020

  Series A financing

  [1]Eucalyptus Healthen.wikipedia.org

  Eucalyptus raises a reported A$8 million Series A.

• 2019

  Eucalyptus Health is founded

  [1]Eucalyptus Healthen.wikipedia.org

  Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko establish the Australian digital-health company.

• 2019

  Pilot launches

  [1]Eucalyptus Healthen.wikipedia.org

  Pilot becomes the company's first specialized telehealth brand, serving men's health needs.

A digitally delivered consumer-health platform that combines specialized telehealth services, clinician-led treatment, prescription fulfillment, and health coaching.

• Men's health telehealth · 2019

  Pilot

  Pilot is Eucalyptus's men's-health service and the company's first major consumer brand. It provides online clinical assessment and treatment pathways for erectile dysfunction, premature ejaculation, hair loss, and weight management. Prescriptions are issued when clinically appropriate and fulfilled through pharmacy partners. The service is positioned around privacy, convenience, and access to treatment without requiring a traditional in-person first appointment.

• Women's health and weight management

  Juniper

  Juniper is focused on women's weight management and menopause care. Its weight-management offering combines clinician assessment, prescription treatment where appropriate, health coaching, and medication delivery. The service has been associated with GLP-1 receptor agonists such as semaglutide and tirzepatide products. Its marketing and prescribing practices have attracted regulatory, professional, and advocacy scrutiny.

• Dermatology

  Software

  Software provides digital dermatology consultations and prescription skincare formulations. Patients submit information for clinical review and may receive personalized treatment plans and products through the company's prescription and fulfillment network. The brand extends Eucalyptus's specialized telehealth model into acne, skin health, and related dermatological concerns.

• Reproductive health

  Kin

  Kin is Eucalyptus's reproductive-health service. It covers areas including contraception, fertility support, and pregnancy care through online clinical services and related treatment pathways. The brand is designed to provide a more convenient digital entry point for reproductive-health consultations while connecting eligible patients with prescriptions and ongoing support.

• Men's preventive health · 2024

  Compound

  Compound is a men's preventive-health program introduced by Eucalyptus in 2024. The service was paused later in the year and relaunched in the United Kingdom in 2025, reflecting the company's experimentation with broader, recurring-care models beyond condition-specific treatment.

• 2026

  Medical-assistant workload allegations

  Current and former Philippines-based medical assistants alleged that performance targets became exceptionally demanding, with reported workloads exceeding 65 queries per day in some cases and increased dependence on AI.

  Source

• 2025

  AI chatbot prompts clinical-governance concerns

  Professional bodies raised concerns after Eucalyptus introduced an AI chatbot into weight-loss services, focusing on the safety and appropriateness of automation in medical care.

  Source

• 2025

  Eating-disorder groups criticize weight-loss marketing

  Peak eating-disorder advocacy organizations expressed concern that aggressive GLP-1 marketing, including social-media activity and a Juniper Black Friday sale, could target people who did not require medication.

  Source

• 2024

  Questions over advertising and editorial boundaries

  Media reporting and ABC's Media Watch examined whether television segments and other coverage promoting Eucalyptus services clearly separated editorial material from advertising.

  Source

• 2023

  Scrutiny of online GLP-1 prescribing

  The RACGP questioned whether remote questionnaires supplied adequate clinical assessment for prescribing GLP-1 receptor agonists, while the TGA warned telehealth companies about advertising prescription-only medicines directly to consumers.

  Source

• 2023

  Compounded semaglutide controversy

  During GLP-1 shortages, Eucalyptus worked with compounding pharmacies to provide compounded semaglutide. Pharmaceutical manufacturers and regulators criticized the practice, followed by an Australian ban on pharmacy compounding of GLP-1 drugs from October 2024.

  Source

Read more

• 2025Juniper Black Friday promotion

  Australia

  Juniper used a Black Friday promotion to market its weight-management offering during a period of heightened public attention to GLP-1 medicines.

  Outcome. Eating-disorder advocacy groups and professional organizations criticized the broader marketing environment, arguing that promotional tactics could encourage treatment among people who did not need it.

  Source
• 2023Influencer and social-media weight-management marketing

  Australia

  Eucalyptus brands used social-media and influencer-led promotion to publicize online weight-management services and treatment outcomes.

  Outcome. Media reports questioned whether some promotional material overstated results or insufficiently communicated the clinical limitations of treatment.

  Source

• 2026

  Sell Eucalyptus to Hims & Hers HealthM&A

  Background

  Eucalyptus had developed an international portfolio of specialized telehealth brands and became an acquisition target for a larger listed consumer-health platform.

  Action taken

  Hims & Hers Health acquired Eucalyptus in a transaction reported at up to US$1.15 billion, with closing consideration, deferred payments, and earn-outs.

  Aftermath

  The deal closed on June 2, 2026. Eucalyptus joined Hims & Hers Health, and Tim Doyle became senior vice president of international operations.

  Maximum reported transaction value. US$1.15 billion (Announced February 2026; completed June 2, 2026)

  Source

• 2024

  Add telephone-based GP consultationsStrategy

  Background

  Professional criticism questioned whether asynchronous questionnaires provided adequate assessment for online prescribing.

  Action taken

  Eucalyptus introduced phone-based general-practitioner consultations alongside or in place of questionnaire-only workflows.

  Aftermath

  The change was intended to strengthen clinical assessment and address concerns about the safety of remote prescribing.

  Source

• 2024

  Launch CompoundProduct launch

  Background

  Eucalyptus sought to broaden its men's-health portfolio beyond condition-specific treatment.

  Action taken

  The company launched Compound as a men's preventive-health program.

  Aftermath

  The program was paused later in 2024 and relaunched in the United Kingdom in 2025.

  Source

• 2023

  Acquire Jenny Craig Australia's digital assetsM&A

  Background

  Jenny Craig Australia entered voluntary administration, creating an opportunity to obtain digital assets associated with the established weight-management brand.

  Action taken

  Eucalyptus acquired the digital assets of Jenny Craig Australia.

  Aftermath

  The transaction expanded Eucalyptus's exposure to digital weight management and supplemented its existing Juniper operations.

  Source

1. 1Eucalyptus Healthen.wikipedia.org
2. 2Eucalyptus Health official websiteeucalyptus.vc